Northwest BiotherapeuticsNWBO
13F holders, Q1 2025 (March 31)8holders −3
0new positions
2sold out
$0.23avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, down 3 from Q4 2024. 0 opened new positions and 2 sold out. The largest holders were Moloney Securities Asset Management, LLC ($114K), VSM Wealth Advisory, LLC ($15K) and Opus Capital Group, LLC ($14K).
- Company
- Northwest Biotherapeutics
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $4K |
All 13F filers, Q4 2024 → Q1 2025: 11,600 shares bought and 13,925 shares sold, net −2,325 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Moloney Securities Asset Management, LLC | 0.02% | Add +2.4% | 500,120 | $114K |
| VSM Wealth Advisory, LLC | 0.01% | No change | 65,574 | $15K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $14K |
| Ethos Financial Group, LLC | 0.00% | No change | 23,700 | $7K |
| Williams Jones Wealth Management, LLC. | 0.00% | No change | 27,000 | $6K |
| KLCM Advisors, Inc. | 0.00% | No change | 10,000 | $2K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $2K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.